BioXcel Therapeutics Stock Rallies Opioid Study Success

Core Insights - BioXcel Therapeutics Inc. shares have increased in premarket trading following positive results from a Phase 2 study of BXCL501 for opioid withdrawal symptoms [1] Study Results - The Phase 2 trial, conducted by Columbia University, indicated that BXCL501 may be as effective or superior to BioCorRx Pharmaceuticals' lofexidine (Lucemyra) in reducing opioid withdrawal symptoms during methadone taper, with a more convenient dosing regimen [2] - Patients receiving BXCL501 240 µg BID experienced over a 30% reduction in Short Opiate Withdrawal Scale-Gossop (SOWS-Gossop) scores, with peak symptom improvement noted on days 3 and 4 [3] - The reduction in withdrawal symptoms with BXCL501 was numerically greater than that observed with lofexidine 0.54 mg administered four times daily, and BXCL501 showed a favorable tolerability profile compared to lofexidine [3] Product Pipeline - BXCL501 is positioned as a "pipeline within a product," with potential applications across various indications, including acute agitation associated with bipolar disorder and schizophrenia [4] - In September 2025, BioXcel Therapeutics released topline exploratory efficacy data from the SERENITY At-Home Pivotal Phase 3 safety trial, demonstrating continued effects and consistent benefits with repeat dosing of BXCL501 [4] Technical Analysis - The stock is trading 1.5% above its 20-day simple moving average (SMA) and 5.2% below its 100-day SMA, indicating short-term strength but longer-term challenges [5] - Over the past 12 months, shares have decreased approximately 76% and are closer to their 52-week lows than highs [5] - The Relative Strength Index (RSI) is at 50.00, indicating neutral territory, while the MACD is at 0.10, below its signal line at 0.15, suggesting bearish pressure on the stock [6] Price Action - BioXcel Therapeutics shares rose 17.58% to $1.94 during premarket trading, with key resistance at $2.00 and key support at $1.50 [7]